Analyst Courtney Breen of Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), boosting the price target to $120.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Courtney Breen has given his Buy rating due to a combination of factors surrounding Gilead Sciences’ recent performance and future prospects. Gilead’s strong financial results in the fourth quarter of 2024, driven by growth in their HIV, oncology, and liver portfolios, have exceeded expectations and provided a positive outlook. Despite anticipated challenges in 2025 due to Part D redesign affecting the HIV treatment market, the company’s strategic initiatives and pipeline advancements in HIV treatment offer reassurance for long-term growth.
Another key factor is the launch of Lenacapavir in HIV pre-exposure prophylaxis (PrEP), expected to be a significant catalyst in 2025, along with the successful performance of the Livdelzi launch. Additionally, Gilead’s efforts to expand its CAR-T franchise into ex-U.S. markets and the promising safety profile of anito-cel in the BCMA CAR-T space further bolster the company’s growth potential. These developments, alongside a raised target price and confidence in Gilead’s strategic execution, underpin Breen’s Buy rating.
In another report released on February 18, Deutsche Bank also upgraded the stock to a Buy with a $120.00 price target.
GILD’s price has also changed dramatically for the past six months – from $74.750 to $110.030, which is a 47.20% increase.